Abstract
Background: Osteonecrosis of the femoral head (ONFH) is a rare disease requiring joint replacement even in young patients due to progressive femoral head collapse. Regenerative medicine is considered the next treatment of interest to prevent collapse. Methods: We percutaneously administered gelatin hydrogel containing 800-µg recombinant human fibroblast growth factor-2 (rhFGF-2) [TRION] to 64 patients with nontraumatic, precollapse, and large ONFHs. Using the endpoint of radiological collapse, we analyzed the joint-preservation period of the historical control comprising patients with nonsurgically treated ONFH. The primary outcome was an expected collapse rate <35% (joint-preservation rate ≥ 65%) at 24 months after rhFGF-2 treatment. We compared the joint-preservation duration with that of an exactly matched historical control (1:1), with radiological collapse as the endpoint. Secondary outcomes were changes in two validated clinical scores (Harris Hip Score [HHS], University of California, Los Angeles [UCLA] score), bone regeneration assessment, and safety. Findings: From 02.17.2016 to 12.07.2016, 64 patients underwent rhFGF-2 treatment. Of the 63 eligible patients, 7 discontinued the trial and were analyzed as worsened cases. The collapse rate was 42 ·9% at 24 months posttreatment. Under the exact matching analyses, median joint-preservation time was significantly higher in the rhFGF-2 group (45·8 months) than in the control group (11·1 months), with a hazard ratio of 2·6 (95% CI 1·5–4·5; p = 0·0003). The ONFHs tended to improve with bone regeneration to smaller ONFHs, according to the postoperative images. The postoperative clinical scores significantly improved, with an increase of 0·15/month for HHS (95% CI 0·03–0·29; p = 0·008) and 0·06/month for UCLA score (95% CI 0·04–0·08; p < 0·0001). 13 serious adverse events were recorded, these cases showed recovery. Interpretation: Our study suggests that rhFGF-2 treatment increases joint-preservation time with clinical efficacy, radiological bone regeneration, and safety. Clinical Trial Registration Details: University Hospital Medical Information Network clinical trials registry (number, UMI20340). Funding Information: Japan Agency for Medical Research and Development. Declaration of Interests: This investigator-initiated trial was supported by competitive grants from the Japan Agency for Medical Research and Development. rhFGF-2 was provided by Kaken Pharmaceutical Co. (Tokyo, Japan). The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article. Ethics Approval Statement: Conducted in accordance with the latest regulatory requirements, including the Declaration of Helsinki and the International Council for Harmonisation - Good Clinical Practice regulations. Approved by the institutional review board or ethics committee of each hospital (Approval number, K023). All patients in TRION provided written informed consent.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.